Mankind Pharma addressed an inquiry from the BSE regarding a notable increase in its security’s trading volume on February 27, 2026. The company confirmed it is fully compliant with all material disclosure requirements and has not withheld any price-sensitive information. Mankind Pharma attributes the recent surge in volume solely to prevailing market conditions, stating it cannot comment further on the external drivers of investor activity.
Official Response to Exchange Inquiry
Mankind Pharma Limited issued a formal clarification on February 27, 2026, in response to a specific query received from the BSE Limited. The inquiry concerned an unusual increase observed in the trading volume of the company’s securities across various exchanges.
Commitment to Disclosure Norms
The company strongly asserted its adherence to the highest standards of governance and compliance. Mankind Pharma affirmed that it is prompt in making all material disclosures as stipulated under relevant regulations. Furthermore, the management confirmed that it has not withheld any event or information that, in its opinion, would reasonably have a bearing on the price or volume behavior of the scrip.
Conclusion on Volume Increase
Following this internal review, Mankind Pharma concluded that the recent spike in trading volume is purely driven by external market conditions. The company formally stated that it is consequently unable to offer any specific comment or explanation regarding the reasons behind this increased trading activity, while maintaining its commitment to timely and accurate regulatory disclosures.
Source: BSE
